Nothing Special   »   [go: up one dir, main page]

ATE213159T1 - Pharmazeutische zusammensetzungen mit mirtazapin und einem oder mehreren selektiven serotonin- aufnahme inhibitoren - Google Patents

Pharmazeutische zusammensetzungen mit mirtazapin und einem oder mehreren selektiven serotonin- aufnahme inhibitoren

Info

Publication number
ATE213159T1
ATE213159T1 AT97201853T AT97201853T ATE213159T1 AT E213159 T1 ATE213159 T1 AT E213159T1 AT 97201853 T AT97201853 T AT 97201853T AT 97201853 T AT97201853 T AT 97201853T AT E213159 T1 ATE213159 T1 AT E213159T1
Authority
AT
Austria
Prior art keywords
pharmaceutical compositions
compositions containing
selective serotonin
uptake inhibitors
serotonin uptake
Prior art date
Application number
AT97201853T
Other languages
English (en)
Inventor
Victor Johannes Nickolson
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8224094&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE213159(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Application granted granted Critical
Publication of ATE213159T1 publication Critical patent/ATE213159T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT97201853T 1996-06-19 1997-06-17 Pharmazeutische zusammensetzungen mit mirtazapin und einem oder mehreren selektiven serotonin- aufnahme inhibitoren ATE213159T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP96201703 1996-06-19

Publications (1)

Publication Number Publication Date
ATE213159T1 true ATE213159T1 (de) 2002-02-15

Family

ID=8224094

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97201853T ATE213159T1 (de) 1996-06-19 1997-06-17 Pharmazeutische zusammensetzungen mit mirtazapin und einem oder mehreren selektiven serotonin- aufnahme inhibitoren

Country Status (25)

Country Link
US (1) US5977099A (de)
JP (2) JP4925074B2 (de)
KR (1) KR100481254B1 (de)
CN (1) CN1132581C (de)
AR (1) AR007609A1 (de)
AT (1) ATE213159T1 (de)
AU (1) AU727851B2 (de)
BR (1) BR9703624A (de)
CA (1) CA2208199C (de)
CZ (1) CZ290691B6 (de)
DE (1) DE69710390T2 (de)
DK (1) DK0813873T3 (de)
ES (1) ES2172744T3 (de)
HK (1) HK1006081A1 (de)
HU (1) HU225534B1 (de)
ID (1) ID17051A (de)
IL (1) IL121076A (de)
NO (1) NO313177B1 (de)
NZ (1) NZ328113A (de)
PL (1) PL188520B1 (de)
PT (1) PT813873E (de)
RU (1) RU2181287C2 (de)
SG (1) SG60073A1 (de)
TR (1) TR199700522A2 (de)
ZA (1) ZA975335B (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL121076A (en) * 1996-06-19 2000-10-31 Akzo Nobel Nv Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
AU737590B2 (en) * 1997-11-14 2001-08-23 N.V. Organon Use of mirtazapine for treating sleep apneas
US6960577B2 (en) * 1998-05-22 2005-11-01 Eli Lilly And Company Combination therapy for treatment of refractory depression
US6727283B2 (en) 1998-10-13 2004-04-27 Pfizer Inc. Sertraline oral concentrate
US6575147B2 (en) * 1999-02-25 2003-06-10 Go-Tec Internal combustion system adapted for use of a dual fuel composition including acetylene
AU781221B2 (en) * 1999-04-19 2005-05-12 Teva Pharmaceutical Industries Ltd. Novel synthesis and crystallization of piperazine ring-containing compounds
US6545149B2 (en) 1999-04-19 2003-04-08 Teva Pharmaceutical Industries Ltd. Synthesis and crystallization of piperazine ring-containing compounds
US6403657B1 (en) * 1999-10-04 2002-06-11 Martin C. Hinz Comprehensive pharmacologic therapy for treatment of obesity
US6759437B2 (en) * 1999-10-04 2004-07-06 Martin C. Hinz Comprehensive pharmacologic therapy for treatment of obesity including cysteine
RU2268725C2 (ru) * 2000-01-19 2006-01-27 Акцо Нобель Н.В. Комбинация лекарственных препаратов, включающая миртазапин, для лечения депрессии и связанных расстройств
WO2002036113A1 (en) * 2000-11-01 2002-05-10 Respiratorius Ab Composition comprising: serotonin receptor antagonists (5ht-2, 5ht-3) and agonist (5ht-4)
US6399310B1 (en) 2001-02-12 2002-06-04 Akzo Nobel N.V. Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
ES2296893T3 (es) * 2001-02-12 2008-05-01 N.V. Organon Uso de mirtazapina para el tratamiento de la depresion severa en un paciente humano y portador del gen de la apolipoproteina e4.
US20030105082A1 (en) * 2001-12-03 2003-06-05 Murphy Greer Marechal Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
US20090311795A1 (en) * 2002-03-21 2009-12-17 Hinz Martin C Bilateral control of functions traditionally regulated by only serotonin or only dopamine
WO2003079886A2 (en) * 2002-03-21 2003-10-02 Hinz Martin C Serotonin and catecholamine system segment optimization techonology
US20070293571A1 (en) * 2006-06-08 2007-12-20 Hinz Martin C Adminstration of dopa precursors with sources of dopa to effectuate optimal catecholamine neurotransmitter outcomes
KR100858852B1 (ko) 2002-12-27 2008-09-17 오쓰까 세이야꾸 가부시키가이샤 기분 장애 치료용 카르보스티릴 유도체 및 세로토닌 재흡수억제제
AR042806A1 (es) 2002-12-27 2005-07-06 Otsuka Pharma Co Ltd Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
MXPA05008943A (es) * 2003-02-21 2005-11-08 C Hinz Martin Tecnologia de optimizacion del segmento de sistema de serotonina y catecolamina.
TW200502222A (en) * 2003-04-02 2005-01-16 Novartis Ag Use of 10-hydroxy-10,11-dihydrocarbamazepine derivatives for the treatment of affective disorders
ES2639579T3 (es) 2003-04-29 2017-10-27 Orexigen Therapeutics, Inc. Composiciones para afectar la pérdida de peso que comprende un antagonista opioide y bupropión
US20050234093A1 (en) * 2003-06-25 2005-10-20 H. Lundbeck A/S Treatment of depression and other affective disorders
US7838029B1 (en) * 2003-07-31 2010-11-23 Watson Laboratories, Inc. Mirtazapine solid dosage forms
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
WO2005023767A2 (en) 2003-09-10 2005-03-17 Brentwood Equities Ltd. Diastereomers of 4-aryloxy-3-hydroxypiperidines
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
TW200538100A (en) * 2004-04-21 2005-12-01 Akzo Nobel Nv Mirtazapine salts
US20060039866A1 (en) * 2004-08-20 2006-02-23 Cypress Bioscience, Inc. Method for treating sleep-related breathing disorders
WO2006055854A2 (en) * 2004-11-17 2006-05-26 Cypress Bioscience, Inc. Methods for reducing the side effects associated with mirtazapine treatment
CA2585317C (en) * 2004-11-19 2015-02-24 N.V. Organon Drug combination for the treatment of depression and related disorders comprising a selective serotonin reuptake inhibitor
PL2135603T3 (pl) 2005-11-22 2013-09-30 Orexigen Therapeutics Inc Kompozycje i sposoby zwiększania wrażliwości na insulinę
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
WO2008060963A2 (en) 2006-11-09 2008-05-22 Orexigen Therapeutics, Inc. Layered pharmaceutical formulations comprising an intermediate rapidly dissolving layer
MX343867B (es) 2006-11-09 2016-11-25 Orexigen Therapeutics Inc Paquete de dosificacion unitaria y metodos para administrar medicaciones de perdida de peso.
WO2008157094A1 (en) * 2007-06-13 2008-12-24 Cypress Bioscience, Inc. Improving the tolerability of mirtazapine and a second active by using them in combination
CN101332193B (zh) * 2007-06-29 2012-12-12 杭州民生药业有限公司 一种马来酸氟伏沙明药物组合物的制备方法
EP2303025A4 (de) 2008-05-30 2012-07-04 Orexigen Therapeutics Inc Verfahren zur behandlung von eingeweidefettbeschwerden
WO2010143628A1 (ja) 2009-06-09 2010-12-16 住友重機械工業株式会社 ハイブリッド式ショベル及びその制御方法
KR101414012B1 (ko) * 2009-11-13 2014-07-01 주식회사 녹십자 아릴피페라진-함유 퓨린 유도체 및 그의 용도
BR112012016783A2 (pt) 2010-01-11 2015-09-01 Orexigen Therapeutics Inc "usos do composto de naltrexona ou sal farmaceuticamente aceitável da mesma a bupropiona ou sal farmaceuticamente aceitável da mesma ou de composição dos mesmos e métodos para proporcionar terapia"
CN102000334B (zh) * 2010-10-15 2012-02-22 北京大学 用于治疗抑郁症的复方制剂
RU2475235C2 (ru) * 2011-03-15 2013-02-20 Общество с ограниченной ответственностью "ЭР ЭНД ДИ ФАРМА" Фармацевтическая композиция для профилактики и лечения депрессивных состояний
JOP20120083B1 (ar) * 2011-04-05 2021-08-17 Otsuka Pharma Co Ltd توليفات تشتمل على بريكس ببرازول أو ملح منه وعقار ثاني للاستخدام في علاج اضطراب cns
KR20240090733A (ko) 2012-06-06 2024-06-21 오렉시젠 세러퓨틱스 인크. 과체중 및 비만의 치료 방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL189199C (nl) * 1975-04-05 1993-02-01 Akzo Nv Werkwijze ter bereiding van farmaceutische preparaten met werking op het centraal zenuwstelsel op basis van benz(aryl)azepinederivaten, de verkregen gevormde farmaceutische preparaten, alsmede werkwijze ter bereiding van de toe te passen benz(aryl)azepinederivaten.
AU8770282A (en) * 1981-08-27 1983-03-03 Shaun R. Coughlin Composition for the treatment of atherosclerosis
US4940585A (en) * 1989-02-17 1990-07-10 Hapworth William E Method for the treatment of nicotine withdrawal syndrome
US5208261A (en) * 1989-12-06 1993-05-04 Akzo N.V. Stabilized solutions of psychotropic agents
DE69005992T2 (de) * 1989-12-06 1994-05-05 Akzo Nv Psychotropische Wirkstoffe enthaltende stabilisierte Lösungen.
US5512593A (en) * 1993-03-02 1996-04-30 John S. Nagle Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor
IL121076A (en) * 1996-06-19 2000-10-31 Akzo Nobel Nv Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
TW587938B (en) * 1997-03-27 2004-05-21 Akzo Nobel Nv Pharmaceutical composition for the treatment and/or prophylaxis of psychotic disorder
JP2001518520A (ja) * 1997-10-03 2001-10-16 キャリー メディカル コーポレイション ニコチンレセプターアンタゴニストおよび抗抑うつ薬または抗不安薬を含有するニコチン嗜癖を治療する組成物

Also Published As

Publication number Publication date
CN1132581C (zh) 2003-12-31
DE69710390D1 (de) 2002-03-21
NO313177B1 (no) 2002-08-26
JP4925074B2 (ja) 2012-04-25
AU727851B2 (en) 2001-01-04
PL188520B1 (pl) 2005-02-28
NZ328113A (en) 1999-09-29
ES2172744T3 (es) 2002-10-01
PT813873E (pt) 2002-06-28
RU2181287C2 (ru) 2002-04-20
CA2208199A1 (en) 1997-12-19
KR100481254B1 (ko) 2005-09-12
HK1006081A1 (en) 1999-02-12
BR9703624A (pt) 1998-09-01
PL320628A1 (en) 1997-12-22
HU9701068D0 (en) 1997-08-28
IL121076A (en) 2000-10-31
NO972816L (no) 1997-12-22
CA2208199C (en) 2006-10-24
CZ187097A3 (cs) 1998-01-14
HUP9701068A3 (en) 2000-07-28
TR199700522A3 (tr) 1998-01-21
AU2612997A (en) 1998-01-08
ZA975335B (en) 1998-01-26
US5977099A (en) 1999-11-02
JP2009137970A (ja) 2009-06-25
CZ290691B6 (cs) 2002-09-11
SG60073A1 (en) 1999-02-22
DK0813873T3 (da) 2002-05-27
KR980000447A (ko) 1998-03-30
MX9704579A (es) 1998-07-31
NO972816D0 (no) 1997-06-18
TR199700522A2 (xx) 1998-01-21
HUP9701068A2 (hu) 1998-08-28
JPH1067663A (ja) 1998-03-10
AR007609A1 (es) 1999-11-10
ID17051A (id) 1997-12-04
DE69710390T2 (de) 2002-08-14
HU225534B1 (en) 2007-02-28
IL121076A0 (en) 1997-11-20
CN1173330A (zh) 1998-02-18

Similar Documents

Publication Publication Date Title
DE69710390D1 (de) Pharmazeutische Zusammensetzungen mit Mirtazapin und einem oder mehreren selektiven Serotonin-Aufnahme Inhibitoren
NO20016198L (no) Orale farmasöytiske sammensetninger som inneholder taxaner og fremgangsmåter for anvendelse av samme i behandling
DE69726015D1 (de) Pharmazeutische zusammensetzung enthaltend koenzym q-10
ATE263558T1 (de) Lipasehemmer und chitosan enthaltende pharmazeutische zusammensetzungen
NO955034L (no) Nye substituerte 1H-imidazoler og farmasöytiske preparater inneholdende disse
DE68925814D1 (de) Hydrogeniertes block-copolymer und dessen zusammensetzung
DE69618587D1 (de) Chinazoline und pharmazeutische zusammensetzungen
DE69634053D1 (de) Oral anzuwendende Arzneizusammensetzung enthaltend 2-Methyl-thienobenzodiazepin
FI954767A (fi) Lipofiilisiä lääkeaineita sisältävä farmaseuttinen koostumus
FI955311A0 (fi) Farmaseuttinen koostumuspohja
BR9506119A (pt) Composição farmacêutica e forma de dosagem farmacêutica unitária
ATE180973T1 (de) Paroxetin enthaltende tabletten und verfahren
NO971811D0 (no) Bicykliske tetrahydropyrazolopyridiner og deres anvendelse som legemidler
HUP9900071A3 (en) Tribenzimidazoles useful as topoisomerase i inhibitors, pharmaceutical compositions containing them and their use
DE59801987D1 (de) Pharmazeutische zusammensetzung enthaltend peptichemio
IS4809A (is) Taxóíð, efnasmíði þeirra og lyfjasamsetning sem inniheldur þau
DE69739855D1 (de) Benzothiophene und denen enthaltende zusammensetzungen
HUP0101733A3 (en) Pharmaceutical compositions containing sulfonyl-dipeptides and their use
DK0815126T3 (da) Bicykliske tachykinin-antagonister, fremstilling deraf og deres anvendelse i farmaceutiske præparater
ITMI950961A0 (it) Composizioni farmaceutiche contenenti gemfibrozil
DE19681529D2 (de) Pharmazeutische Darreichungsform
ITMI962628A0 (it) Composizione farmaceutica
IT1272935B (it) Composizione farmaceutica contenente n-acetil-cisteina
IS4909A (is) Spíró-píperidín afleiður og notkun þeirra sem lyfjafræðilegra miðla
IT1288113B1 (it) Composizioni farmaceutiche effervescenti contenenti sobrerolo

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee